REGN Financial Facts
Income tax benefit: -101.08MLoss from operations: 362.8M
See Full Income Statement
Deferred revenue from Sanofi: 529.79M
Accounts payable and accrued expenses: 714.92M
See Full Balance Sheet
Regeneron Pharmaceuticals, Inc. (REGN) Earnings
|
Expand Research on REGN
| Next EPS Date | 2/8/24 | EPS Growth Rate | -14.8% |
|---|---|---|---|
| Average EPS % Beat Rate | +11.6% | Revenue Growth Rate | -4.4% |
| Average % Move 1-Wk after EPS | -0.0% | Normal Earnings Time | Before Open |
| Date | Qtr | EPS | Cons. | Surprise | Revs | Cons. | Gd. | 1-Week % | 1-Day % | Details | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2/8/24 | Q423 | N/A | $10.70 | N/A | N/A | $3.26B | N/A | N/A | N/A | ||
11/2/23  |
Q323 | N/A | $10.75 | N/A | N/A | $3.23B | N/A | N/A | N/A | ||
| 8/3/23 | Q223 | $10.24 | $9.85 | +$0.39 | $3.16B | $3.03B | N/A |  | | Details | |
| 5/4/23 | Q123 | $10.09 | $9.56 | +$0.53 | $3.16B | $3B | N/A | | | Details | |
| 2/3/23 | Q422 | $12.56 | $10.17 | +$2.39 | $3.41B | $3.13B | N/A | | | Details | |
| 11/3/22 | Q322 | $11.14 | $9.82 | +$1.32 | $2.94B | $2.94B | N/A | | | Details | |
| 8/3/22 | Q222 | $9.77 | $8.60 | +$1.17 | $2.86B | $2.79B | N/A | | | Details | |
| 5/4/22 |  |
Q122 | $11.49 | $10.04 | +$1.45 | $2.97B | $2.73B | N/A | | | Details |
